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A 47-year-old man with a history of heart transplant was admitted after severe traumatic brain injury and seizures. During
mechanical ventilation, the patient developed bronchospasm that severely compromised respiratory function that led to cardiac
arrest. After resuscitation, application of isoﬂurane through the Anaesthetic Conserving Device (AnaConDa) in the ICU
successfullytreated bronchospasm,providedadequatesedation,andenabledappropriateventilationanddiagnosticbronchoscopy.
A subsequent bronchoalveolar lavage revealed a high amount of Herpes simplex DNA. Herpes simplex pneumonia was diagnosed
andtreated withacyclovir.Isoﬂuranetreatmentwasappliedfortwelvedaystotalwithoutsideeﬀectsonrenalandcerebral function.
The patient recovered quickly after the termination of sedation. At discharge, he was fully awake without focal neurological
deﬁciencyandhislong-termoutcomewasexcellent. Thiscasedemonstratesthatisoﬂuraneisatreatmentoptioninlife-threatening
cases of bronchospasm and a safe option for long-term sedation.
1.Introduction
The volatile anesthetic drug isoﬂurane reduces respiratory
resistance and can be applied to treat severe bronchospasm
[1, 2]. Though isoﬂurane is typically administered only for
a short period for general anesthesia, it may also be a viable
treatment option for severe bronchospasm and for sedation
during critical care. However, little experience has been had
with long-term treatment of isoﬂurane (>1 week) or use
in patients with traumatic brain injury due to concerns
regarding renal toxicity and increased intracranial pressure.
This case report illustrates the successful long-term
application of isoﬂurane in a critically ill patient with several
underlying comorbidities.
2.CaseReport
A fully conscious 47-year-old man was transferred to the
hospital after collapse and severe head injury. Twelve years
prior tothis incident,thepatientunderwent heart transplan-
tation for treatment of dilatative cardiomyopathy. At admis-
sion, computer tomography (CT) revealed traumatic brain
injury with an occipital skull fracture, left frontal contusion
bleedings, and a traumatic subarchnoid hemorrhage. On the
second day of hospitalization, he suddenly suﬀered from
general seizures associated with severe arterial hypotension.
After intubation and resuscitation, the patient was treated
with anticonvulsants and sedative drugs. A new CT scan
excluded any new cerebral injuries or bleedings.
The patient was then transferred to the ICU. In the
presence of fever and clinical and laboratory signs of sys-
temicinﬂammation, calculatedantimicrobial treatment with
clindamycinandciproﬂoxacinwasinitiated.Routineclinical,
radiological, and microbiological examinations, however,
did not reveal any sources of infection. An attempt to
reduce sedation to better assess neurological status resulted
in severe bronchospasm and impaired lung function as
indicated by wheezing and a markedly prolonged expiratory2 Case Reports in Medicine
phase. Dynamic hyperinﬂation occurred and ﬁnally led to
hypoxia and to cardiac arrest. Cardiopulmonary resuscita-
tion was performed, and lung function was compromised
with a paO2/FiO2 ratio of 225 at high airway pressures.
Consequently, increasing doses of sedatives became nec-
essary and a combination of midazolam (60mg·h−1),
ketamin (200mg ·h−1), clondine (120µg·h−1), and sufen-
tanil (75µg·h−1) was needed to protect the patient from
any stimuli during positioning and to prevent additional
severe events of bronchospasm. We administered the bron-
chodilators salbutamol (1.5mg) and ipratropium bromide
(500µg) as aerosole three times per day, magnesium sulfate
(20mmol) intravenously and theophylline (400mg loading
dose over 20min, then 40mg·h−1) intravenously. Theo-
phylline dose was then adjusted to maintain therapeutic
blood levels between 10 and 20mg·L−1 [3]. Both chest X-
ray and spiral chest CT scan showed small pleural eﬀusion
but again no sign of pneumonia. Repeated microbiological
examinations and cultures of tracheal aspirates, urine, or
catheter tips did not document any pathogens. A diagnostic
bronchoscopy for bronchoalveolar lavage (BAL) was halted
dueto life-threatening episodesofbronchial obstruction and
bronchospasm.
On day 12 after admission, recurrent episodes of bron-
chospasm led to an increase of arterial pCO2 to 63mmHg.
At this point, still unable to provide adequate sedation,
we decided to start inhalative isoﬂurane therapy with the
Anaesthetic Conserving Device Conserving Device (Ana-
ConDa, Sedana Medical, Sundbyberg, Sweden). Inspiratory
gas concentration was set to 0.6% which led to Ramsay-
score of 5 to 6 points. This allowed appropriate ventilation
and adjustment of pCO2 to a concentration of 38mmHg.
IV sedation could then be reduced stepwise. Bronchoscopy
was repeated successfully and revealed rigid mucus and a
highly sensitive bronchial tree that reacted to mild stimuli
with bronchoconstruction. Despite this impediment, we
performed a bronchoalveolar lavage in the right band, left
lowerlobes(Segments7or8,resp.).Microbiologicalcultures
of the lavage did not reveal bacterial or fungal growth
and polymerase chain reaction (PCR) for cytomegalovirus
DNA was also negative. However, PCR for Herpes sim-
plex Typ 1 (HSV-1) virus DNA revealed a high load of
9,300,000 genomic equivalents (ge) mL−1.I nt h et h r o a t
lavage 19,000,000gemL−1,H S V - 1w a sf o u n d .
Following this discovery, antiviral treatment with acy-
clovir was initiated. Dosage was adjusted to 2 × 800mg i.v.
according to renal function. Over the next few days, both
intensity and frequencyof bronchospasm decreased. Sixdays
after the beginning of the antiviral treatment, isoﬂurane was
safely reduced in a stepwise manner and was stopped after
a 12-day treatment period. Over the next few weeks, HSV-1
DNA concentrations consistently decreased in throat lavage
to6,200,000gemL−1 onday8andto250,000gemL−1 onday
17 of acyclovir treatment. The patient had had a history of
impaired renal function and suﬀered from acute renal failure
on day 5 after admission, which made renal replacement
therapy necessary from hospital day 5 to 10. However, when
isoﬂurane was initiated,renal function had already recovered
(Figure 1), and the patient did not require renal replacement
therapy any longer.
Neurologically, the patient recovered quickly after the
termination of sedation. Atdischarge, hewas fully awakeand
had no focal neurological deﬁciency.
Tracheostomy was performed on hospital day 19 to
facilitate weaning from the ventilator. On day 39, the patient
was eased oﬀ mechanical ventilation. He was transferred to
a rehabilitation centre 40 days after hospital admission. At
discharge, he was fully awake and had no focal neurological
deﬁciency.
Seven months after the event, the patient was discharged
from rehabilitation with no neurological deﬁciencies. Long-
term outcome (as assessed by phone call) was excellent.
3.Discussion
In our patient suﬀering from several morbidities, isoﬂurane
allowedtotreatlive-threateningbronchospasm andprovided
long-term sedation. Bronchospasm was most likely caused
by HSV-1 pneumonia. While chest X-ray and CT scan did
not show alveolar inﬁltrates typical for bacterial pneumonia,
pulmonary function was severely compromised due to
airway hypersensitivity. High concentrations of HSV-1 DNA
was detected in BAL, but no other sign of bacterial or fungal
infection was found after microbiological cultures and DNA
analyses.
Patients treated with immunosuppressive drugs are espe-
cially prone to HSV pneumonia and other viral infections.
In patients who have HSV pneumonia and are undergoing
mechanical ventilation, this is frequently associated with
deteriorated lung function and weaning failure, even in the
presence of normal X-ray ﬁndings [4, 5]. HSV-1 pneumonia
is associated with markedly decreased survival during ICU
treatment [6–8]. When Linssen et al. examined patients
with a positive BAL for HSV-1, they found a considerably
increased 14-day mortality rate for patients with an HSV-1
load larger than 105 gemL−1 [7]. In their study, mortality
rose from 20% to 41% in patients with a viral load above
that cutoﬀ value. In some cases, HSV pneumonia may lead
to severe obstructive lung disease.
Our case demonstrates the successful application of
isoﬂurane in the ICU, for a prolonged period of time, for
treatment of refractory bronchospasm. Though our patient
had no history of asthma, the underlying HSV-1 pneumonia
was associated with severe bronchospasm during mechanical
ventilation. Over the course of the disease, intravenous
sedative drugs did not achieve adequate sedation level. Espe-
cially during positioning and nursing care maneuvers, severe
bronchospasm caused life-threatening cardiac depression.
The application of bronchodilatory drugs had no beneﬁcial
eﬀect.
In patients with traumatic brain injury, control of
arterial pCO2 levels is of upmost importance and excludes
permissive hypercapnia as a treatment option. In this
case, the additional application of the volatile anesthetic
isoﬂurane enabled controlled mechanical ventilation and a
stable control of pulmonary gas exchange. Finally, isoﬂuraneCase Reports in Medicine 3
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Figure 1: Creatinine clearance of the patient during hospital
treatment. Time of isoﬂurane treatment is indicated by grey
background.
treatment enabled successful bronchoscopy and BAL which
resulted in diagnosis of the underlying infection.
While concerns have been raised about isoﬂurane possi-
blycausingincreasedintracranial pressure,ithas beenshown
during neurosurgical procedures that when applied below
expired concentrations of 1.2%, isoﬂurane does not lead to
anyincrease inintracranial pressure [9,10].Thismakesthese
drugs suitable for sedation in traumatic brain injury.
Though volatile anesthetics have been shown to be
eﬀective in acute asthmatic bronchospasm, data on pro-
longed application is rare [11]. A common concern against
the prolonged use of volatile anesthetics is their potential
harm to renal function. During short-term use for surgical
procedures, several perioperative studies could not ﬁnd
a deterioration of renal function in patients with pre-
existing renal insuﬃciency after isoﬂurane anesthesia, but
data for long-term application for more than one week is
limited [12–15]. Sackey and coworkers compared isoﬂurane
sedation in the ICU to sedation by midazolam in 40
patients for an observation period up to 96 hours [16]. In
that study, suﬃcient sedation using isoﬂurane was reached
without occurrence of hepatic or renal adverse events. In
particular, patients receiving immunosuppressive therapy
are known to have impaired renal function and decreased
creatinine clearance. Our patient with a 12-year history
of immunosuppression had experienced his ﬁrst incident
of acute renal failure one year prior to this event during
diarrhea, and during our care he had experienced another
episode after cardiopulmonary resuscitation which required
renal replacement therapy. When isoﬂurane therapy was
started, the patient was already recovering from acute renal
failure, and renal replacement therapy had been stopped.
Application of isoﬂurane did not deteriorate renal function
and the time course of serum creatinine levels, blood urea,
and creatinine clearance during isoﬂurane therapy can be
seen in Figure 1. At discharge, creatinine clearance was in
normal range (75mL/min).
Of note in this case was the use of the AnaConDa
system for isoﬂurane delivery [17]. While most modern
ventilators allow the appliance of sophisticated respiratory
therapeutic regimes, they usually have no delivery method
for volatile anesthetics. The AnaConDa system—which is
essentially a modiﬁed heat-moisture exchanger—is directly
connected to the patient’s endotracheal tube and can be
combined with any respirator. The device is approved for
use with eitherisoﬂurane or sevoﬂurane, which are delivered
by a syringe. Sackey and coworkers reported a remarkably
lower consumption of isoﬂurane using the AnaConDa
delivery method than from traditional vaporizer techniques
and an environmental pollution below the internationally
recommended long-term exposure limits which make side
eﬀects on ICU personnel unlikely [18].
W h i l ei s o ﬂ u r a n e ,i nt h i sc a s e ,w a sa b l et oc o n t r o lt h e
patient’s pulmonary situation and secure suﬃcient ventila-
tion, the volatile anesthetic could not be safely withdrawn
until the primary source of the bronchospasm was treated.
Here, byday 6 of acyclovirantiviral therapy, inspiratory con-
centrations of isoﬂurane were able to be reduced stepwise,
andisoﬂuranetreatmentwasabletobestoppedonedaylater.
To conclude, our case shows the successful long-term
application of isoﬂurane, for a 12-day period, in a patient
with severe HSV-1 pneumonia. The application of the
volatile anesthetic permitted the therapy of refractory bron-
chospasm, enabled diagnosis of HSV-1 pneumonia, helped
to control pCO2 levels, and led to suﬃcient sedation.
The use of isoﬂurane did not aggravate pre-existing renal
insuﬃciency and was safely performed in a patient with
traumatic brain injury.
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